Stoke Therapeutics stock maintains Buy rating at H.C. Wainwright on positive study data

Stoke Therapeutics (NASDAQ:STOK) received a reiterated Buy rating from H.C. Wainwright, with the price target adjusted to $35 from $47, reflecting a revised valuation model accounting for market sentiment and increased cost of capital. This follows positive open-label extension (OLE) study data for zorevunersen, a potential first-in-class therapy for Dravet Syndrome, which demonstrated clinically meaningful improvements in five core Vineland subdomains and an 80-87% median reduction in seizure frequency. These encouraging results support the design of the pivotal Phase 3 EMPEROR trial, expected to commence in Q2 2025, and highlight zorevunersen's potential to address a significant unmet need for cognitive and intellectual improvements in Dravet Syndrome patients.

Analysis

H.C. Wainwright's reiterated Buy rating on Stoke Therapeutics (STOK) is underpinned by highly encouraging open-label extension (OLE) data for its Dravet syndrome candidate, zorevunersen. The analysis revealed "clinically meaningful gains" across five core Vineland subdomains and a significant 80-87% median reduction in seizure frequency, results that were absent in natural history cohorts. This data strengthens the thesis for the upcoming pivotal Phase 3 EMPEROR trial, set for Q2 2025, and enhances the drug's commercial profile as a potential first-in-class therapy addressing cognitive function, a key unmet need. However, the accompanying price target reduction from $47 to $35, despite the positive clinical news, highlights a critical valuation headwind. The revision reflects broad market factors, including a "heightened cost of capital" and lower institutional risk appetite for early-stage assets, rather than a flaw in the drug's potential. With the stock trading at $11.86, there is a substantial disconnect between the current market price and analyst valuations, indicating the market is heavily discounting the execution risk of the Phase 3 trial.

Key Decisions for Investors

• Investors with a higher risk tolerance could consider the significant gap between the current stock price and the $35 analyst target as a potential entry point, given the strong de-risking data from the open-label extension study.
• The primary focus should be on the upcoming Phase 3 EMPEROR trial, scheduled to begin in Q2 2025, as its outcome represents the most significant catalyst and potential inflection point for the company's valuation.
• Be mindful that macroeconomic pressures, such as the high cost of capital and risk-off sentiment for clinical-stage biotechs, are suppressing valuation and may continue to do so until the Phase 3 data provides definitive validation.